Merck Reaches Mutual Agreement with Ono Pharmaceutical to Terminate the License Agreement on Ceralifimod
18-Jun-2014
- Germany
Merck Serono, the biopharmaceutical division of Merck, remains committed to improving the lives of people with MS, and will continue to pursue external collaborations and internal development programs aimed at identifying and developing high quality candidate molecules with the goal of making a real difference in the lives of people with MS.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.